Imp-3 epitope peptides for th1 cells and vaccines containing the same

Abstract

Isolated IMP-3-derived epitope peptides having Th1 cell inducibility are disclosed herein. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce IMP-3-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.

1 . An isolated peptide having 10-30 amino acids in length and comprising a part of the amino acid sequence of SEQ ID NO: 6, wherein said peptide comprises an amino acid sequence selected from the group consisting of:
 (a) a contiguous amino acid sequence having more than 9 amino acids in length selected from the amino acid sequence of SEQ ID NO: 1; and   (b) an amino acid sequence in which one, two or several amino acids are substituted, deleted, inserted, and/or added in the amino acid sequence of (a), wherein said peptide has ability to induce T helper type 1 (Th1) cells.   
     
     
         2 . The isolated peptide of  claim 1 , wherein the peptide or fragment thereof has abilities to bind at least two kinds of MHC class II molecules. 
     
     
         3 . The isolated peptide of  claim 2 , wherein the MHC class II molecules are selected from the group consisting of HLA-DR8, HLA-DR53, and HLA-DR14. 
     
     
         4 . An isolated polynucleotide encoding the peptide of  claim 1 . 
     
     
         5 . A composition for comprising one or more peptide(s) of  claim 1 , or one or more polynucleotide(s) encoding them. 
     
     
         6 . The composition of  claim 7 , wherein said composition further comprises one or more peptides having CTL inducibility. 
     
     
         7 . A method for inducing an APC having an ability to induce a Th1 cell, said method comprising a step of contacting an APC with the peptide of  claim 1  in vitro, ex vivo or in vivo. 
     
     
         8 . A method for inducing an APC having an ability to induce a CTL, said method comprising a step selected from the group consisting of:
 (a) contacting an APC with the peptide of  claim 1  in vitro, ex vivo or in vivo; and   (b) introducing a polynucleotide encoding the peptide of  claim 1  into an APC.   
     
     
         9 . A method for inducing a Th1 cell, said method comprising a step selected from the group consisting of:
 (a) co-culturing a CD4-positive T cell with an APC that presents on its surface a complex of an MHC class II molecule and the peptide of  claim 1  or fragment thereof; and   (b) introducing a polynucleotide encoding both of T cell receptor (TCR) subunits, or polynucleotides encoding each of TCR subunits into a CD4-positive T cell, wherein the TCR can bind to a complex of an MHC class II molecule and the peptide of  claim 1  or fragment thereof presented on cell surface.   
     
     
         10 . A method for enhancing an immune response mediated by an MHC class II molecule, wherein the method comprises a step of administering to one or more peptide(s) of  claim 1 . 
     
     
         11 . A method of inducing an immune response against cancer in a subject in need thereof, said method comprising the step of administering to the subject a composition comprising one or more peptide(s) of  claim 1 .